Genocea Biosciences
Genocea Biosciences was a Cambridge, Massachusetts biopharmaceutical company that developed cancer immunotherapies using its ATLAS platform to identify patient-specific T-cell targets. Its investigational programs included the GEN-009 neoantigen vaccine and GEN-011 peripheral T-cell therapy. Founded in 2006, it announced an orderly wind-down of operations in May 2022.
Key facts
| Business Model | Licensing |
|---|---|
| CAGE Code | 54JS6 |
| Legal Name | Genocea Biosciences, Inc. |
| Company Operating Status | Closed |
| Full Address | 100 Acorn Park Dr Cambridge, MA 02140 |
| Previous Name | GENOCEA BIOSCIENCES INC |
| Stock Symbol | GNCA |
| Ticker Symbol | GNCA |
| Wellfound ID | genocea-biosciences |
Contact details
Email and phone for Genocea Biosciences are available to signed-in members of CliffBio.
Sign in to view